President Trump plans to sign an executive order accelerating research into psychedelic drugs for mental health treatment, according to senior administration officials. The order targets compounds including LSD, Ecstasy, and psilocybin, which have shown promise in treating PTSD, depression, and other conditions. It also allocates $50 million for state-level research into ibogaine, a powerful psychedelic from Central Africa.

The measure aims to reduce federal restrictions that have hampered scientific study of these substances. Texas will be the primary beneficiary, having already committed $50 million to ibogaine research for opioid use disorder. The order directs the FDA, DEA, and Department of Justice to streamline approval processes while maintaining safety standards.

Administration officials emphasized the urgency given the opioid epidemic and rising veteran suicide rates. The goal is to issue approvals within weeks, eliminating delays that have slowed potential treatments. Terminally ill patients would also gain access to investigational drugs that have passed early clinical trials but await final FDA approval.